Related Experiment Video
Updated: May 3, 2026
An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
Published on: July 20, 2014
SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner
Terry W Moody1, Daniel C Chan2, Samuel A Mantey3
1Department of Health and Human Services, National Cancer Institute, Center for Cancer Research, Office of the Director, Bethesda, MD 20892, USA.
Aims:
The mechanism by which SR48692 inhibits non-small cell lung cancer (NSCLC) proliferation was investigated.
Main Methods:
The ability of SR48692 to inhibit the proliferation of NSCLC cell lines NCI-H1299 and A549 was investigated in vitro in the presence or absence of neurotensin (NTS). The ability of NTS to cause epidermal growth factor receptor (EGFR) transactivation was investigated by Western blot using NSCLC cells and various inhibitors. The growth effects and Western blot results were determined in cell lines treated with siRNA for NTSR1.
Key Findings:
Treatment of A549 or NCI-H1299 cells with siRNA for NTSR1 reduced significantly NTSR1 protein and the ability of SR48692 to inhibit the proliferation of A549 or NCI-H1299 NSCLC cells. Treatment of A549 and NCI-H1299 cells with siRNA for NTSR1 reduced the ability of NTS to cause epidermal growth factor receptor (EGFR) transactivation. SR48692 or gefitinib (EGFR tyrosine kinase inhibitor) inhibited the ability of NTS to cause EGFR and ERK tyrosine phosphorylation. NTS transactivation of the EGFR was inhibited by GM6001 (matrix metalloprotease inhibitor), Tiron (superoxide scavenger) or U73122 (phospholipase C inhibitor) but not H89 (PKA inhibitor). NTS stimulates whereas SR48692 or gefitinib inhibits the clonal growth of NSCLC cells.
Significance:
These results suggest that SR48692 may inhibit NSCLC proliferation in an EGFR-dependent mechanism.
Insights
SR48692 inhibits non-small cell lung cancer (NSCLC) growth by affecting the epidermal growth factor receptor (EGFR) pathway. This study clarifies the mechanism behind SR48692
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related deaths worldwide.
- Understanding the molecular mechanisms underlying NSCLC proliferation is crucial for developing targeted therapies.
- The neurotensin receptor 1 (NTSR1) pathway has been implicated in cancer progression.
Purpose of the Study:
- To investigate the mechanism by which SR48692 inhibits NSCLC proliferation.
- To elucidate the role of neurotensin (NTS) and epidermal growth factor receptor (EGFR) signaling in NSCLC growth.
- To determine if SR48692's inhibitory effects are EGFR-dependent.
Main Methods:
- In vitro proliferation assays using NSCLC cell lines (NCI-H1299, A549) treated with SR48692, with or without NTS.
- Western blot analysis to assess EGFR transactivation and signaling pathway activation (ERK).
- RNA interference (siRNA) targeting NTSR1 to evaluate its role in NTS-mediated signaling and SR48692 efficacy.
Main Results:
- Silencing NTSR1 significantly reduced NSCLC cell proliferation and NTS-induced EGFR transactivation.
- SR48692 and gefitinib (an EGFR inhibitor) suppressed NTS-mediated EGFR and ERK tyrosine phosphorylation.
- NTS stimulated NSCLC clonal growth, while SR48692 and gefitinib inhibited it.
Conclusions:
- SR48692 inhibits NSCLC proliferation through an EGFR-dependent mechanism.
- The neurotensin receptor 1 (NTSR1) plays a role in mediating NTS effects on NSCLC growth and EGFR signaling.
- These findings suggest SR48692 as a potential therapeutic agent for NSCLC targeting the EGFR pathway.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...